Rhenium (186Re) obisbemeda by Plus Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how Rhenium (186Re) obisbemeda's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.Rhenium (186Re) obisbemeda overviewRhenium (186Re) obisbemeda is under development for the treatment of recurrent glioblastoma multiforme, breast cancer, head and neck squamous cell carcinoma, head and neck cancer, triple-negative breast cancer (TNBC), leptomeningeal and peritoneal carcinomatosis, liver cancer, lung cancer, melanoma, ovarian carcinomatosis and pediatric central nervous system cancers including ependymoma, high grade glioma, brain cancer and diffuse intrinsic pontine glioma. It is administered through intratumoral, intrathecal and intraperitoneal routes. The drug candidate comprises of N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-chelated rhenium nanoliposomes and developed based on rhenium nanoliposome (RNL) technology. Plus Therapeutics overviewPlus Therapeutics, formerly Cytori Therapeutics Inc is a developmental-stage pharmaceutical company, which focuses on the discovery, development, and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. The company’s pipeline of candidate drug products includes Doceplus, a patented albumin-stabilized Pegylated liposomal formulation of docetaxel; Doxoplus, a complex, injectable, generic Pegylated liposomal formulation of doxorubicin; BMEDA-chelated rhenium nanoliposome (RNL); and a co-encapsulated, doxorubicin and rhenium nanoliposome (DRNL). It uses a proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics. Plus Therapeutics is headquartered in Irvine, Texas, the US. For a complete picture of Rhenium (186Re) obisbemeda's drug-specific PTSR and LoA scores, buy the report here.
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC).
What's Your Reaction?
